221 related articles for article (PubMed ID: 21552209)
1. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.
Hong SM; Li A; Olino K; Wolfgang CL; Herman JM; Schulick RD; Iacobuzio-Donahue C; Hruban RH; Goggins M
Mod Pathol; 2011 Sep; 24(9):1237-47. PubMed ID: 21552209
[TBL] [Abstract][Full Text] [Related]
2. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
3. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.
Foo WC; Rashid A; Wang H; Katz MH; Lee JE; Pisters PW; Wolff RA; Abbruzzese JL; Fleming JB; Wang H
Hum Pathol; 2013 Jun; 44(6):1024-30. PubMed ID: 23260327
[TBL] [Abstract][Full Text] [Related]
4. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.
Cao D; Zhang Q; Wu LS; Salaria SN; Winter JW; Hruban RH; Goggins MS; Abbruzzese JL; Maitra A; Ho L
Mod Pathol; 2007 May; 20(5):570-8. PubMed ID: 17396143
[TBL] [Abstract][Full Text] [Related]
6. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
7. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
[TBL] [Abstract][Full Text] [Related]
8. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Ma N; Zhang L; Bian JM; Cao HY
Tumour Biol; 2013 Aug; 34(4):2309-13. PubMed ID: 23568706
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
[TBL] [Abstract][Full Text] [Related]
10. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
[TBL] [Abstract][Full Text] [Related]
11. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.
Handra-Luca A; Hong SM; Walter K; Wolfgang C; Hruban R; Goggins M
Br J Cancer; 2011 Apr; 104(8):1296-302. PubMed ID: 21448168
[TBL] [Abstract][Full Text] [Related]
12. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins.
Handra-Luca A; Hammel P; Sauvanet A; Lesty C; Ruszniewski P; Couvelard A
J Clin Pathol; 2014 Apr; 67(4):295-300. PubMed ID: 24170210
[TBL] [Abstract][Full Text] [Related]
13. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
14. Anterior gradient 2 and mucin 4 expression mirrors tumor cell differentiation in pancreatic adenocarcinomas, but aberrant anterior gradient 2 expression predicts worse patient outcome in poorly differentiated tumors.
Brychtova V; Hermanova M; Karasek P; Lenz J; Selingerova I; Vojtesek B; Kala Z; Hrstka R
Pancreas; 2014 Jan; 43(1):75-81. PubMed ID: 24177142
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
[TBL] [Abstract][Full Text] [Related]
17. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
19. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
[TBL] [Abstract][Full Text] [Related]
20. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
Matsubayashi H; Infante JR; Winter J; Klein AP; Schulick R; Hruban R; Visvanathan K; Goggins M
Cancer Biol Ther; 2007 Oct; 6(10):1569-75. PubMed ID: 18000398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
